重症COVID-19 ICU患者侵袭性肺部真菌感染的发生情况
该研究在法国5个ICU对145例重症SARS-CoV-2相关肺炎患者进行真菌筛查,发现 probable/putative 侵袭性肺霉菌感染仅7例(4.8%)且与高死亡率相关,实体器官移植受者风险显著升高(OR=4.66),而无基础免疫抑制者风险较低。
要点
- 重症COVID-19无免疫抑制者侵袭性真菌重叠感染风险低,尤其是曲霉病。
- 实体器官移植受者发生侵袭性肺霉菌感染风险显著升高(OR=4.66)。
- 真菌检测假阳性或临床无关定植见于25例(17.2%),无需启动抗真菌治疗。
核心结论
- 在无基础免疫抑制的重症SARS-CoV-2相关肺炎患者中,侵袭性真菌继发感染风险较低,尤其是曲霉病。
研究设计与样本
- 研究纳入法国5个ICU收治的重症SARS-CoV-2相关肺炎患者145例,均进行呼吸道和血清真菌筛查。
- 中位年龄55岁,男性104例(72%),超重99例(68%),高血压83例(57%),糖尿病46例(32%)。
- 既往存在侵袭性真菌感染宿主危险因素者仅20例(14%)。
- 全部患者接受有创机械通气,73例(54%)接受体外膜氧合支持。
- 共进行2815次真菌学检测(培养、半乳甘露聚糖、β-葡聚糖和PCR),涉及475份呼吸道样本和532份血清。
主要发现
- probable/putative 侵袭性肺霉菌感染诊断7例(4.8%),并与高死亡率相关。
- 多因素分析显示实体器官移植受者风险显著升高(OR=4.66;IQR 1.98-7.34;P=0.004)。
- 假阳性真菌检测或临床无关定植且无需启动抗真菌治疗者25例(17.2%)。
临床怎么用
- 对无免疫抑制的重症COVID-19患者,常规广谱真菌筛查可能识别出低概率的侵袭性霉菌感染。
- 实体器官移植受者应警惕侵袭性肺霉菌感染风险,考虑加强真菌监测。
- 注意真菌检测假阳性及临床无关定植,避免不必要的抗真菌治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Whether severe coronavirus disease (COVID-19) is a significant risk factor for the development of invasive fungal superinfections is of great medical interest and remains, for now, an open question.Objectives: We aim to assess the occurrence of invasive fungal respiratory superinfections in patients with severe COVID-19.Methods: We conducted the study on patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia admitted to five ICUs in France who had respiratory and serum sampling performed for specific screening of fungal complications.Measurements and Main Results: The study population included a total of 145 patients; the median age was 55 years old. Most of them were male (n = 104; 72%), were overweight (n = 99; 68%), and had hypertension (n = 83; 57%) and diabetes (n = 46; 32%). Few patients presented preexisting host risk factors for invasive fungal infection (n = 20; 14%). Their global severity was high; all patients were on invasive mechanical ventilation, and half (n = 73, 54%) were on extracorporeal membrane oxygenation support. Mycological analysis included 2,815 mycological tests (culture, galactomannan, β-glucan, and PCR) performed on 475 respiratory samples and 532 sera. A probable/putative invasive pulmonary mold infection was diagnosed in 7 (4.8%) patients and linked to high mortality. Multivariate analysis indicates a significantly higher risk for solid organ transplant recipients (odds ratio, = 4.66; interquartile range, 1.98-7.34; P = 0.004). False-positive fungal test and clinically irrelevant colonization, which did not require the initiation of antifungal treatment, was observed in 25 patients (17.2%).Conclusions: In patients with no underlying immunosuppression, severe SARS-CoV-2-related pneumonia seems at low risk of invasive fungal secondary infection, especially aspergillosis.
引用
- Fekkar A, Lampros A, Mayaux J, et al. Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. Am J Respir Crit Care Med. 2021. PMID: 33480831. doi:10.1164/rccm.202009-3400OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。